Novartis: JH389 is a probiotic product, not a medication, and has significant limitations as a dietary supplement.

People’s Finance News, March 30—On March 30, MennoHua (603538) released a notice regarding unusual stock trading fluctuations. JH389 is a probiotic product; it is not a drug, and as it exists as a dietary supplement, it has many limitations. The company’s in-development product JH389 is a probiotic; in the future, it plans to launch it as a dietary supplement, and it is currently still in the research and trial stage. The preliminary trial data has limitations. The JH389 probiotic product’s sample size in the domestic study was 28 cases, conducted as an 8-week small-scale, limited-scope feeding trial. Because the sample size is relatively limited, the general applicability of its conclusions needs to be further verified in a larger population, and the conclusiveness of its conclusions is not yet sufficient. The product faces fairly intense competition. Weight-loss-related non-drug products include probiotic-type products, other dietary supplements, health foods, meal replacements, and functional foods, among other categories, all broadly participating in the competition. At present, there are many market participants, categories are becoming increasingly diverse, and the competitive landscape in the industry is relatively intense.